Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2019 Long-term Follow-up in Healthy Volunteers
NCT04932824Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCB-2019 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Incidence of Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) and Serum anti-SCB-2019 IgG antibody titers. Started Jan 2021; status: completed.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04932824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932824.